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Intra-graft CD20þ B-cell clusters are found during acute
rejection of renal allografts and correlate with graft recovery
following rejection injury. Here using archived kidney tissue
we conducted immunohistochemical studies to measure
specific subsets of pathogenic B cells during graft rejection.
Cluster-forming CD20þ B cells in the rejected graft are likely
derived from the recipient and are composed of mature
B cells. These cells are activated (CD79aþ ), and present
MHC Class II antigen (HLADRþ ) to CD4þ T cells. Some of
these clusters contained memory B cells (CD27þ ) and they
did not correlate with intra-graft C4d deposition or with
detection of donor-specific antibody. Further, several
non-cluster forming CD20 B-lineage CD38þ plasmablasts
and plasma cells were found to infiltrate the rejected
grafts and these cells strongly correlated with circulating
donor-specific antibody, and to a lesser extent with
intra-graft C4d. Both CD20þ B cells and CD38þ cells
correlated with poor response of the rejection to steroids.
Reduced graft survival was associated with the presence
of CD20 cells in the graft. In conclusion, a specific subset
of early lineage B cells appears to be an antigen-presenting
cell and which when present in the rejected graft may
support a steroid-resistant T-cell-mediated cellular rejection.
Late lineage interstitial plasmablasts and plasma cells may
also support humoral rejection. These studies suggest
that detailed analysis of interstitial cellular infiltrates may
allow better use of B-cell lineage specific treatments to
improve graft outcomes.
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CD20þ lymphocytic infiltrates have been demonstrated to be
potentially pathogenic in transplant cellular acute rejection
(AR), correlating with a phenotype of a rejection that is more
recalcitrant to conventional treatment, an increased risk of
graft loss, and independent of C4d peritubular deposition.1–6
Other studies have not always shown this clinical correla-
tion,7–9 and it is unclear if these differences may, in part, be
related to the patient group under study with underlying
differences secondary to recipient age, the variability of
specific transplant center induction and immunosuppression
protocols, or because of differences in the specific lineage of
CD20þ B cells observed in different types of graft rejection.1
Detailed phenotypic analyses of CD20þ B-cell infiltrates
in graft rejection have not been performed to date. Given the
number of immunohistochemistry stains required to com-
prehensively phenotype the lineage of infiltrating B cells
and the limitation of human renal biopsy tissue available
post-diagnostic evaluation, these studies are difficult to
perform extensively on patient samples. With this in mind,
tissue microarrays using transplant nephrectomies offer the
best (if not ideal) alternative to biopsies for screening
of possible immunohistochemical (IHC) predictors of graft
outcome. Moreover, the transplant nephrectomy patients
are often weaned off all immunosuppression prior to surgery,
resulting in uninhibited full-blown immunological attack on
the allograft. In our study, we have attempted to capture this
phenotype of severe AR, utilizing tissue microarray tools,
with a focus on the different lineages of infiltrating B cells in
graft rejection.
RESULTS
Comprehensive immunostaining was performed initially on
kidney tissue microarray (K-TMA) samples and selected,
relevant immunostains were then performed in core biopsy
samples with rejection, and the results were correlated with
specific clinical graft outcomes.
Distinct B-cell lineages in rejecting grafts
Two predominant lineages of B cells were identified at the
time of AR (Figure 1a): interstitial CD20þ B-cell clusters and
interstitial scattered CD38þ plasmablasts and plasma cells.
Fluorescence in situ hybridization (FISH) for the X and Y
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chromosomes in sex-mismatched donor and recipient
pairs suggests that the B cells in AR were recipient derived
(Figure 1b–e).
CD20þ clusters. As elucidated by the K-TMA immuno-
stains, the CD20þ B-cell clusters were of early lineage, with
an activated phenotype, with positive staining for CD79a.
Few, but not all cluster cells positive for CD20 and negative
for CD3, expressed the CD27 marker, suggesting that B-cell
clusters contain some memory B cells (Figure 2a; Figure S3).
B-cell clusters also stained positive for MHC Class II
(HLADR; Figure 2b), and were surrounded by CD4þ
lymphocytes, suggesting a putative role of CD20þ cells in
antigen presentation.10 Occasional CD8þ cytotoxic T cells and
CD68þ macrophages were also seen in the B-cell aggregates.
Dense interstitial CD20þ B-cell aggregates1,2,5 were seen in
53% (17/32) of core biopsy samples with graft rejection.
The follicular dendritic cell network as highlighted by CD21
was seen in the CD20þ clusters in 11% of core biopsies
(Figure 3a).
CD38þ plasmablasts and plasma cells. Another predomi-
nant population of B cells in graft rejection consists of
CD38þ plasmablasts and plasma cells. Many of these cells co-
segregate with plasma cells, which are positive for CD138 and
negative for early B-lineage markers (Figures 1a and 2c).
CD38þ -rich cellular infiltrates were seen in 59% (19/32) of
core biopsies. Many AR biopsies contained both CD20þ
clusters and CD38þ B-lineage cells (in 44% (14/32) of core
biopsies).
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Figure 1 | Different B-cell subsets populate rejecting kidney allografts (a) and these B cells are recipient derived (b–e). (a) Two
different B-cell subsets are identified in AR: representative renal allograft core biopsies were stained for H&E, CD20, and CD38 markers. Two
major nonoverlapping populations of B cells are seen and these include CD20þ but CD38 cells mostly in clusters (upper panel) and CD20
but CD38þ interstitial plasmablasts and plasma cells (lower panel, original magnification  200). The CD20þ and CD38þ cells can be
seen in the interstitium, surrounding the tubules, but not causing tubulitis (original magnification  300). (b–e) CD20þ B-cell clusters in
rejecting kidney allografts are recipient derived. FISH for X (green signal) and Y (red signal) chromosome probes was performed on all
K-TMA cores and a representative core with AR (T-11) from a male recipient of a female donor kidney is shown here (original magnification
 400). CD20 stain and FISH were performed on consecutive sections to be able to locate the B-cell clusters on FISH sections accurately.
As shown, the tubule is from a female donor kidney (XX, b) and the B-cell clusters seen in the interstitium are likely recipient derived
(XY, c), although few Y-chromosome-positive cells within the B-cell cluster may also be colocalizing T cells or macrophages.
The serial section stained with CD20 is also shown, corresponding to the area of the tubule (d) and B-cell cluster (e).
Kidney International (2008) 74, 664–673 665
V Zarkhin et al.: Intra-graft B cells in renal allograft rejection o r i g i n a l a r t i c l e
CD20 CD79a CD45RB
Blimp-1 Pax-5 Bcl6
CD38 CD138 C4d
CD20 CD27 CD3
H&E CD20 HLADR
CD68 CD4 CD8
Figure 2 | Characterization of the phenotype of B-cell subsets observed in rejecting K-TMA cores. Multiple immunostains were
performed on consecutive K-TMA sections. To localize the B-cell clusters accurately, CD20 immunostains were performed on five different
K-TMA sections with other immunostains (mentioned in text) performed on intervening sections. (a) Phenotype of CD20þ B-cell clusters in
representative T-TMA cores. CD20þ B-cell clusters are also positive for CD79a, CD45RB, and Pax-5, but negative for Blimp-1, Bcl6, CD38, and
CD138; C4d stain is negative in this core (original magnification  200 top panel). These B cells appear to be of early lineage (Pax-5þ ) with
activated phenotype (CD79aþ and CD45RBþ ). Representative staining from another core (bottom panel, original magnification  400) shows
that a subset of CD20þ B cells in cluster have a memory B-cell phenotype (CD27þ but CD3). Some of the CD27þ cells appear to be memory
T cells (CD3þ and CD27þ ). The CD20, CD27, and CD3 stains were performed on consecutive sections. (b) Antigen-presenting capacity of
CD20þ cells. CD20þ B cells are HLADRþ , and are surrounded by CD4þ helper T cells, suggesting a possible B-cell role in antigen presentation.
Very few CD68þ and HLADRþ macrophages and dendritic cells are seen in these clusters. A few CD8þ T cells are also seen (original
magnification  200). (c) Phenotype of interstitial CD38þ cells. The second B-cell subset consists of late lineage cells, plasmablasts, and plasma
cells. These CD38þ areas also stain for CD138, but are negative for CD20, Pax-5 (early B-lineage markers), and CD45RB. A smaller component
of CD79aþ , Bcl6þ , and Blimp-1þ cells are also seen in these areas. In addition to these B-lineage cells, infiltrating T lymphocytes (CD3þ )
and macrophages (CD68þ ) are also seen in these non-clustering interstitial areas. C4d is negative in this K-TMA core (original magnification
 200). On H&E, the CD38þ areas are rich in plasma cells and, in some cases, eosinophils (inset, original magnification  600).
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Rejection episodes also had a variable density of infiltrat-
ing CD4þ and CD8þ T lymphocytes, CD68þ macrophages,
and eosinophils in the interstitium, whereas CD8þ T cells
appeared to cause most of the tubulitis. Other cell surface
activation markers on infiltrating cells in rejection (CD23 and
CD30) were mostly negative (Table S1B).
C4d, donor-specific antibody, and B-cell subsets in graft
rejection
C4d stain was scored as positive if seen in peritubular
capillaries.13 C4dþ rejections were noted in 25% (8/32)
of core biopsies (Table S2B). Circulating donor-specific
antibody (DSA) was detected in 17/26 C4d biopsies (65%)
and 7/8 of C4dþ core biopsies (88%). Neither C4d nor
DSA detection correlated with the presence of CD20þ
clusters, as previously reported,1,2,5 or with CD138þ plasma
cells in graft rejection. The presence of circulating DSA
correlated strongly with intra-graft CD38 staining (P¼ 0.01;
r¼ 0.42) and weakly with peritubular C4d (P¼ 0.04; r¼ 0.3)
(Table S2B).
Phenotyping infiltrates and chemokines in K-TMA specimens
K-TMA samples had extensive graft rejection and an
overarching finding was that the intensity of the infiltrate
specific for CD8þ T cells, CD68þ macrophages, CD20þ
clusters, and STAT-1 mononuclear cell staining correlated
with a strong inflammation score (P¼ 0.0001; r¼ 0.55).
Endothelial cells and infiltrating lymphocytes within
CD20þ clusters, as well as CD38þ cells, showed expression
for CXCL12þ and VEGF-A. Scattered CXCL13 and
CXCR5-positive lymphocytes were seen mainly in CD20þ
clusters (Po0.0001; r¼ 0.67) (Figure 3a),11,14 as previously
published.11
A heat-map has been generated for ease of visualization of
27 IHC stains on the 50 K-TMA samples (Figure 3b). On the
basis of the similarity of staining scores (see Table S1A and
B), a dendrogram on the x axis shows that these 50 samples
segregate into three groupings or clusters. Cluster-I rejection
samples lack CD20 aggregates, but have CD38 and C4d
staining, supporting a predominant humoral rejection.
Cluster-II rejection samples, despite being nephrectomy
samples with AR, have less intense interstitial inflammation;
as expected, they segregate with normal K-TMA samples.
Cluster-III rejection samples have dense CD20þ infiltrates, as
well as CD38þ and C4d, suggesting that these samples may
have a mixed, cellular, and humoral rejection.
For the three clusters observed from the K-TMA sam-
ples, there were no obvious demographic differences, no
H&E CD38 CD138
CD20 CD79a CD45RB
Blimp-1 Pax-5 Bcl6
CD68 CD3 C4d
Figure 2 | Continued.
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differences for recipient/donor age and sex, donor type
(living vs deceased), number of previous transplants, days of
graft survival, incidence of delayed graft function, antibody
titers prior to transplant, HLA mismatches, or the Banff
AR grade at the time of nephrectomy.15,16 Graft survival data
were not correlated with K-TMA immunostain results, as
graft survival data can be flawed in a K-TMA data set, based
on the fact that nephrectomies can often be performed well
after complete loss of graft function. On the basis of
previously published results, a single correlation analysis
was conducted between treatment responsiveness of the AR
episode just prior to the nephrectomy, and it was noted that
a failure of response to first-line pulse steroid therapy
(requiring antibody therapy, that is, ‘steroid resistance’)
CD20 CD21
CXCR5CXCL13
VEGF
STAT-1
CXCL12
Figure 3 | Putative role of chemokines in modulating the trafficking of B-cell subsets (K-TMA immunostains). (a) Signals for the
CD20þ cell trafficking. CD20þ B-lymphocyte clusters colocalize rarely with CD21þ follicular dendritic network. A few CXCL13þ and
CXCR5þ cells are seen in these clusters as previously published.11 CD20þ clusters (stain not shown) also co-express CXCL12, VEGF-A,
and STAT-1 (right panel, original magnification  200). (b) Cellular infiltrates and trafficking signals in AR visualized by hierarchical clustering
of K-TMA immunostains. Fifty nephrectomy specimens utilized for the generation of the K-TMA (Table S1A and B), were stained with
27 individual IHC stains (also see Materials and Methods). As shown here, the individual biopsies are clustered on the x axis and the
immunostains on the y axis. K-TMA samples with rejection are labeled red, K-TMA normal nephrectomy samples are labeled green. Antibody
stains were scored semiquantitatively in 2 to 2 scale to allow for variation of stains in a two-color system, with red being maximal at
þ 2 and green being minimal at 2. The stains (rows) and samples (columns) are clustered on the basis of the overall similarity in the
expression pattern using hierarchical clustering by Cluster, with visualization of data in TreeView.12 As seen here by the dendrogram
on the x axis segregating sample similarity, K-TMA samples clustered in three distinct subgroups. Cluster-I (15 samples; T40, 17, 03, 13, 29,
21, 15, 33, 27, 31, 20, 14, 12, 38, and 10) lack CD20þ aggregates, but have severe inflammation (scores 2–3) and prominent accumulation
of CD38þ cells. Cluster-III samples (17 samples; T11, 37, 32, 22, 7, 24, 6, 35, 18, 34, 26, 19, 8, 36, 16, 25, and 23) had dense CD20þ
aggregates, which were also CD79aþ , HLADRþ , and segregate with CD4þ T cells, as described in Results. Rejection samples in
Cluster-II (T30, 5, 43, 9, 39, 1, 41, 02, 28), colocalizing with normal samples (N1-7) had mild inflammation, fewer infiltrates, and the
least tubular atrophy.
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occurred more frequently in Cluster-III (the samples with
CD20þ cluster infiltrates) compared with Cluster-I (75 vs
27%; P¼ 0.007).
Phenotyping infiltrates in core biopsies, with clinical
correlations
On the basis of the most informative K-TMA IHC results,
selected immunostains (CD20, CD21, CD38, CD138, CD27,
C4d, CD45RB, CD79a, and D240) were performed on core
renal allograft biopsies (n¼ 37; 32 Banff-graded AR and 5
stable protocol biopsy controls). Protocol biopsies without
graft rejection were negative for all selected immunostains,
except positive D240 staining for lymphatics. In biopsies with
AR, the density of CD20þ and CD38þ staining, but not
C4dþ or Banff AR grade, individually correlated with
resistance to steroid therapy. Specifically, steroid resistance
was seen in 14/17 CD20þ cases, 15/15 CD38þ biopsies
(Po0.0001), and in only 2/8 C4dþ cases. In contrast, only
2/15 CD20 and 4/17 CD38 cases were steroid resistant.
Intra-graft CD20þ cells were predominantly found in ARs
occurring later post transplantation (50±35 months for
CD20þ AR vs 22±23 months for CD20 AR; P¼ 0.03), and,
as previously noted, CD20þ graft rejections were at an
increased risk of graft loss (P¼ 0.0006; r¼ 0.58; Table S2B).
Ten rejection biopsies had graft loss at the current follow-up
(Table S2B). CD38 positivity in graft rejection, on the other
hand, did not correlate with graft survival.
Non-adherence with immunosuppressive medications
appeared to be a major cause of AR in the CD20þ vs the
CD20 group (71 vs 11%; P¼ 0.01) as well as the CD38þ vs
the CD38 group of rejections (73 vs 23%; P¼ 0.007). As
expected, patients with graft loss after rejection were more
likely to be adolescents (mean age at rejection for patients
with graft loss vs no graft loss: 16.7±3.7 vs 12±5.3 years;
P¼ 0.02).
Association of vascular and lymphatic markers with B-cell
subsets
As B cells have been found to associate with lymphoid neo-
genesis and lymphangiogenesis,17–19 whereas endothelial
venules and the microvasculature may be specific entry
routes for lymphocytes, K-TMA and core biopsies with graft
rejection were stained with D240 and CD34, to ascertain any
association with the localization of B-cell infiltrates. Gain
in lymphatic density, by formation of new lymphatics in the
graft, was seen with graft rejection (Figure 4), as previously
shown.20,21 Although lymphangiogenesis was seen in rejec-
tion-related lymphocytic infiltrates, including B-cell clusters,
it was not specifically associated with B-cell infiltration,
did not correlate with time post transplantation or the risk
of graft loss following rejection. On the basis of CD34
staining, a reduction of graft microvasculature was seen
in graft rejection (Figure 4), with no correlation to B-cell
infiltration or time post transplantation.
DISCUSSION
An extensive analysis of acute transplant rejection in human
renal allografts has demonstrated that two specific lineages of
B cells can form a significant part of the graft infiltrate.
Although elucidating the exact role of these cells would require
comprehensive cell culture or animal studies, based on existing
literature and this extensive study of human biopsies, we can
hypothesize about the function of B cells in graft rejection.
CD20þ B-cell clusters, previously identified in graft rejec-
tion, appear to consist of activated cells of early B-cell lineage;
these cells may have a memory phenotype and express MHC
Class II and colocalize with CD4þ T cells. We hypothesize
that these B-cell clusters may form follicular dendritic net-
works and expand into proliferating, antigen-specific CD20þ
cells, which survive and can develop a memory phenotype in
the presence of continued antigen exposure22 and persistent
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Figure 4 | K-TMA cores with increased number of graft lymphatics (D240þ ), and reduced microvasculature (CD34þ ) in AR. K-TMA
cores were stained for lymphatic marker D240 as well as endothelial marker CD34 (original magnification  200). Left: control normal
kidney; right: K-TMA with rejection. The numbers of lymphatics (D240þ ) and peritubular capillaries (CD34þ ) per 2 mm core were
counted. The number of D240þ vessels was significantly (P¼ 0.002) increased in cases with AR (T1-43) compared with control samples
(N1-7). (53.8±78.3 vessels/core in K-TMA AR vs 12±9.5 vessels/core in K-TMA normal samples; P¼ 0.002). Conversely, density of
microvasculature, highlighted by CD34þ stain per core was strongly reduced (Po0.0001) with rejection.
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chronic graft inflammation, all likely occurring in rejection
episodes resulting from immunosuppression non-adherence.
It has been previously shown that chronically inflamed
organs can demonstrate ectopic germinal center formation
with B-cell activation, and plasma cell differentiation
can occur locally.23,24 However, no definite germinal centers
are seen in this data set, limiting the mechanistic hypothesis
for the formation and evolution of B-cell clusters in graft
rejection. On the basis of the IHC studies and clinical
correlates, it is likely that B-cell clusters in rejection can func-
tion as efficient antigen-presenting cells, expressing MHC
Class II to present processed antigen to CD4 helper T cells,
thus driving a C4d-independent, T-cell-dependent cellular
rejection, resistant to conventional treatment. It is likely that
variations, in part, in the clinical association of CD20þ B-cell
clusters and graft outcomes5,7,8 may be related to differences
in the phenotypes of B-cell clusters or differences in the
mechanisms of AR escape in these studies. These data are also
supported by the K-TMA analysis, which reveals that in
Cluster-III, the K-TMA samples with prominent CD20
infiltration during AR, strongly correlates with failure of
response to first-line pulse steroid therapy.
Extensive infiltration with CD38þ cells is also seen in graft
rejection. CD38 is not entirely specific for cells of plasma cell
lineage25 as it is also expressed on early cells of B and
T lineages, NK cells, monocytes, and macrophages. Recog-
nizing this, we have performed sequential stains for B cell,
T cell, and macrophage markers, and these studies show that
many of the CD38þ cells in graft rejection are plasmablasts
and plasma cells. Semiquantitative scoring for CD38þ cells is
easier to perform than CD138 staining alone, as CD38 does
not have the background tubular epithelial staining of CD138
that makes scoring difficult especially in the setting of tubular
atrophy.26 CD38 has the added advantage of highlighting
plasmablasts27–29 (Figure S5). The lack of significant correla-
tion of CD138 staining with either DSA or C4d in this study
may be due to suboptimal semiquantitative scoring for
CD138 due to background epithelial staining, and may also
relate to the number of biopsies studied.
CD38þ cells (mostly plasmablasts and plasma cells)
correlate weakly with intra-graft C4d and very strongly with
circulating DSA and may be the progenitor pool for long
lived, antibody-producing plasma cells, driving a humoral
rejection. The association of an increased incidence of
humoral rejection with medication non-adherence, as seen
in this study, has also been previously demonstrated.30 The
weak correlation between C4d and DSA seen in our study
may be due to possible evanescent nature of C4d staining,16,31
immunosuppression usage differences, detection methods for
C4d,32 or recipient pediatric age. The loss of micro-
vasculature in AR might also have contributed to the
lower incidence of C4d detection (8/32 or 25%) in this
study. Thus, CD38 staining may be an alternative IHC
marker for detection of antibody-mediated rejection, parti-
cularly, in the absence of robust intra-graft C4d staining. It is
important to reiterate that the clinical significance of both
CD20 and CD38 markers is relevant only in the presence of
acute graft rejection, as they can be seen in infiltrates within
subcapsular scar, and in the setting of reflux nephropathy and
acute pyelonephritis (N Kambham, unpublished data).
B cells are known to induce lymphangiogenesis17–19 and
increased B-cell infiltrates in graft rejection may drive the
increased number of observed lymphatics with rejection. It
has also been previously suggested that B cells, primed
against donor antigen from secondary lymphoid organs, may
arrive to the graft from the blood stream through the efferent
lymphatics of the secondary lymphoid organs,20,33 and then
exit the graft through newly formed lymphatics. As there is
no specific correlation in our study between lymphangio-
genesis and the B-cell clusters, some of the B-cell transits into
and out of the graft may be occurring by other, undefined
mechanisms.
Various chemokines seem to play a role in the movement
of and interactions between various lymphocyte subsets;
a subset of chemokines in this study were chosen based on
their correlation with the B-cell signature in graft rejection1
(http://sarwal.stanford.edu/Bcell), to investigate if they were
specifically associated with B-cell infiltration and clusters.
CXCL12 and STAT-1 expression correlated with all infiltrat-
ing lymphocytes, including B cells. CXCL12 has been shown
to influence the homing of different lymphocytes to the graft,
including naive and mature B cells and may also support the
persistence of long-lived plasma cells.34 STAT-1 mediates
activation of macrophages and antigen-presenting cells, and
stimulates expression of MHC, co-stimulatory, and adhesion
molecules,35,36 on activated T and B cells. CXCL12 appears to
be nonspecific chemoattractants for different lymphocyte
subsets. VEGF-A, CXCL13, and CXCR5 may support B-cell
clusters and B-cell trafficking.11
With the observation that this B-cell pool can be seen
more often in rejections occurring late post transplantation,
it can be postulated that these cells, produced late in the
immune response, have a competitive advantage to displace
earlier emigrants. These B cells may then be well primed to
present antigen to activated T-helper cells and support a
robust cellular rejection based on T-cell-dependent B-cell
activation. In the absence of therapies directed specifically
against this B-cell pool, incomplete treatment of this cellular
rejection could be anticipated, resulting in the poor observed
transplant outcomes.
Thus, as we discover that various infiltrating cells in
the allograft (such as B cells) can have multiple functions, for
example, efficient antigen presentation, T-cell activation,
antibody production, and secretion of pro-inflammatory
cytokines, all dependent on their various stages of differen-
tiation (Figure 5), it is obvious that AR episodes can no
longer be considered a generic event. The K-TMA analysis
offers some insights into distinct subclasses of AR, weighted
by the predominance of certain B-cell infiltrates. An
individualized IHC analysis of rejection episodes may be
warranted to uncover differing mechanisms supporting and
driving rejection injury, so that initial rejection therapy can
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be modified and more specifically tailored in a timely
manner. Specific characterization of B-cell lineages in
rejection could offer unique opportunities for development
of targeted rejection therapy. Rituximab, humanized mono-
clonal antibody against CD20þ cells, has been found to have
efficacy against recalcitrant rejection6,37–40 and may derive
its efficacy from its depletion of the B-cell pool, which is
persistently presenting antigen. Further studies are required
to validate if CD38þ /CD20 plasmablasts and plasma cells,
correlative with DSA levels, could also be a potential marker
for humoral rejection. If validated, targeted therapy, such
as the development of a monoclonal antibody against CD38
or intravenous immunoglobulin, and plasmapharesis,41
may be desirable for CD38þ B-cell-rich rejection episodes.
Eventually, tailored immunomodulation of rejection episodes
may be the critical intervention required for the effective
reversal of immunological injury and improved long-term
graft survival.
MATERIALS AND METHODS
Tissue and patient information
Histological analyses and IHC stains were performed on K-TMA
generated using 2 mm cortex cores from 50 normal (n¼ 7) and
transplant nephrectomy specimens (n¼ 43), as well as on 37 renal
allograft 18-gauge needle biopsies from functioning grafts with
normal histology (n¼ 5; protocol biopsies) and AR (n¼ 32). All
biopsies were adequate by Banff 1997 Criteria and the presence of
AR was determined by established criteria.15,16 All K-TMA samples
had evidence of AR qualified by tubulitis in preserved renal cortex,
interstitial inflammation, and presence/absence of vasculitis. The
K-TMA was used as a screening tool for the initial, multiple,
and sequential IHC stains due to paucity of allograft biopsy
material. For details of K-TMA generation, please refer to the web
supplement (http://sarwal.stanford.edu/Bcell; Figures S1 and S2). As
AR in transplant nephrectomies occurs in the context of markedly
reduced or absent immunosuppression, and is thus aggressive
and not necessarily the same as rejections seen earlier during the
post-transplant course, a subset of 37 patient core biopsies were
also chosen for further evaluation of selected, informative K-TMA
IHC stains. All the IHC staining procedures performed involved
endogenous peroxidase blocking steps as well as the appropriate
positive and negative controls, including the use of an isotype-
matched immunoglobulin for the latter (Figure S4).
Relevant clinical data were collected on all patients, including
date of transplant, type of transplant, HLA match, donor source,
donor and recipient age, and immunosuppression (baseline and at
rejection). Data were also captured for infection (including protocol
measurements of viremia loads for CMV and EBV by peripheral
blood quantitative PCR and urinary tract infection), graft function
(calculated creatinine clearance by the Schwartz formula42), recovery
of graft function (defined as return of calculated creatinine clearance
to within 10% the baseline pre-AR value, 6 weeks after AR), acute
Figure 5 | Summary hypothesis of the phenotype and relevance of B-cell subsets in kidney graft rejection. Naive B cells attain
full maturation in the bone marrow and migrate to lymph nodes where antigen presentation occurs. Activated B cells recirculate to the
injured graft in rejection through newly formed afferent lymphatics, in response to CXCL13, STAT-1, and VEGF. Recipient-derived CD20þ
B cells may efficiently present donor antigen (HLADRþ ) to primed CD4þ T cells, and, on repeated antigenic exposures, may differentiate
into high affinity memory B cells that can persist in the graft in ‘ectopic’ follicles, supporting a T-cell-dependent cellular rejection.
Specific therapeutics depleting CD20þ B cells (such as monoclonal antibody against CD20/Rituximab) may be of benefit. Further
differentiation of activated and memory B cells to early and late CD38þ plasmablasts and long-lived plasma cells, result in circulating
DSA and humoral rejection. Specific therapies should focus on removal of DSA (intravenous immunoglobulin or TPE/plasmapharesis),
and rather than only target CD20þ cells, also consider targeted depletion of CD38þ cells.
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and chronic rejection grades,15,16 circulating DSA at rejection, and
time to graft loss. Details of the clinical characteristics of the samples
used for the K-TMA and the core biopsies are available on the web
supplement at Tables S1A and B, and S2A and B, respectively.
Written informed consent was obtained from study patients,
and the study was approved by the Institutional Review Board of
Stanford University (ID no. 79516 and 75791).
Immunohistochemistry
All slides were stained with H&E (hematoxylin and eosin) and then
used for grading AR, chronic graft injury,15 and for documentation
of plasma cells and eosinophils. On K-TMA slides, 27 IHC stains
were performed for B-cell lineage (CD20, CD45RB, CD79a, Pax-5,
Bcl-6, Blimp-1, CD21, CD23, CD27, CD38, and CD138), T-cell
lineage (CD3, CD4, and CD8), macrophages (CD68), HLADR,
chemokines and growth factors (CXCL12, CXCL13, CXCR5, VEGF,
and STAT-1), endothelial cells (CD34), lymphatics (D240), viral
markers (SV40, CMV, and EBV in situ hybridization), CD30, and
C4d using commercially available antibodies. The following antigens
are expressed in various stages of B-cell development: CD20: mature
B cells, CD21: follicular dendritic network; CD79a: mature B cells up
until plasma cell differentiation, CD27: memory B and T cells, Pax-
5: early B cells, Bcl6: germinal center B cells, Blimp-1: mature B cells
committed to plasma cell differentiation, CD38: plasmablasts and
plasma cells, and CD138: plasma cells.
Selected IHC stains including H&E, CD20, CD38, CD138, CD21,
CD27, CD79a, CD45RB, C4d, and D240 were performed on patient
core biopsies. B-cell aggregates (CD20þ ) were defined as dense
clusters of B-lymphocytes, measuring 4275 cells/h.p.f.1 Our studies
are based on the presence of at least 275 cells/h.p.f. rather than
counting the actual number of cells. A CD20 case has many fewer
cells (less than 100 cells/h.p.f.). IHC evidence of infection,
lymphoproliferative disorder, or calcineurin inhibitor toxicity was
excluded from study. All study patients had negative urine cultures
and negative immunostains for CMV, EBV, and polyoma virus
(antisera to SV40). The sources of the antibodies and corresponding
dilutions are detailed in Table S3.
Semiquantitative histological scoring of K-TMA and core
biopsies
Kidney tissue microarray samples. For most stains, slides were
scored blindly by a single pathologist (NK) in a semiquantitative
manner. The scoring methodology follows previously published TMA
scoring systems.26 Stain scores were calculated on a numerical basis
from 0 to 3 based on intensity and extent of staining across individual
compartments of renal parenchyma (tubules, glomeruli, vessels, and
interstitium) and the infiltrating inflammatory cells. Details of scores
generated for each of the stained antibodies are provided in Table S1B.
In general, the parenchymal staining was scored as 0, no staining; 1,
weak and focal; 2, strong, o50% of the cortex; 3, strong, 450% of
the cortex; the inflammatory infiltrate was scored as 0, no staining; 1,
rare cells; 2,o30% infiltrate positive; 3,430% infiltrate positive. The
C4d stain in the peritubular capillaries was scored as o5%¼ 0;
5–20%¼ 1; 20–50%¼ 2; 450%¼ 3; glomerular capillary wall stain-
ing was also noted. Binary scoring (positive¼ 1; negative¼ 0) was
used for CD20 and CD38 stains; positive implying dense CD20þ
clusters1 or extensive CD38 staining (430% of the infiltrate).
Fluorescence in situ hybridization staining
XY chromosome FISH analysis was performed on deparaffinized
K-TMA sections (of which 22 were sex mismatched), using probes
for X (DXZ1; Spectrum green) and Y (DYZ3; Spectrum orange)
chromosomes, and fluorescence was visualized (CytoVision; Applied
Imaging, San Jose, CA, USA) using an Olympus BH51 microscope
with multiple filters. Results were correlated with H&E and CD20-
stained tissue sections. CD20 stain and FISH were performed on
consecutive sections to be able to locate the B cells on FISH
accurately. Figure 1b–e shows representative staining on a single core
(T11) from a male recipient with a female kidney.
Statistical analysis
T-test, Mann–Whitney–Wilcoxon test, w2, Fisher’s exact, and
Jonckheere–Terpstra tests were used for parametric and nonpara-
metric continuous variable and categorical variable comparisons.
Two-tailed P-value was reported and Po0.05 was considered
statistically significant. Spearman’s and Pearson’s correlation coeffi-
cients were calculated for clinical outcomes and IHC cell marker
stains on the K-TMA and patient core biopsies. All statistical
analyses were performed using SAS 9.1.2 (SAS Institute Inc., Cary,
NC, USA). Certain results are presented in the format of mean±
standard deviation. Semiquantitative K-TMA immunostaining
scores were tabulated with the TMA-Deconvoluter program,43
converting scores to a 2 to þ 2 normalized scale based on the
0–3 scale (0¼2, 1¼1, 2¼ 1, and 3¼ 2) to feed the Cluster
program. Hierarchical clustering method was performed by Cluster
program12 to cluster patients and IHC cell marker stains based on
centered correlation similarity metrics; the more similar they are, the
closer they sit. TreeView program12 was used to visualize the
hierarchical clustering.
Supplementary information
Additional information on methods, clinical information, IHC
images, and analytic methods is available in supplementary
appendices at http://sarwal.stanford.edu/Bcell.
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SUPPLEMENTARY MATERIAL
Figure S1. The K-TMA slide used for this study.
Figure S2. Representative K-TMA cores: 23 out of 28 performed IHC
stains on representative 2-mm K-TMA cores of one normal kidney and
four transplant nephrectomies.
Figure S3. Presence of memory B and T cells in intra-graft
lymphocyte clusters. Two representative 2-mm kidney tissue
microarray (K-TMA) cores.
Figure S4. Representative negative control of K-TMA for CXCL13.
Figure S5. Representative CD38-positive biopsy core (C10).
Table S1A. Summary of the clinical characteristics of 43 samples
with transplant kidney nephrectomies used in tissue microarray
studies.
Table S1B. Clinical and pathological characterization of transplant
kidney nephrectomies used in K-TMA and antibody staining score.
Table S2A. Clinical and pathological characterization of biopsy
samples from dysfunctional kidneys.
Table S2B. Clinical and pathological characterization of 37 biopsy
samples from 28 dysfunctional kidneys and IHC.
Table S3. Antibodies used for IHC staining.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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